Ovarian Tissue Freezing For Fertility Preservation

The purpose of this study is to offer an alternative method to women who wish to preserve the possibility of fertility, as well as to learn more about the ability of human eggs to survive and function after long term storage in frozen ovaries (ovarian tissue cryopreservation). The study will seek to preserve ovarian tissue and reproductive potential for patients whose medical or surgical treatment may harm ovaries or remove ovarian tissue.

Sex

Female

Minimum age

18 Years

Maximum age

41 Years

Inclusion Criteria:

* Woman between the age of 18-41 years who will undergo surgery, chemotherapy, drug treatment and/or radiation for the treatment or prevention of a medical condition or malignancy expected to result in permanent and complete loss of subsequent ovarian function or have a medical condition or malignancy that requires removal of all or part of one or both ovaries.
* Patients may have newly diagnosed or recurrent disease. Those who were not enrolled at the time of initial diagnosis are eligible if they have not received therapy that is viewed as likely to result in complete and permanent loss of ovarian function.
* For patients undergoing elective removal of an ovary for fertility preservation only, have two ovaries.
* Patients who already have stored cryopreserved ovarian tissue in a frozen state prior to undergoing cancer treatments (surgery, chemotherapy or radiation) will be eligible for enrollment with informed consent.
* Signed an approved informed consent and authorization permitting the release of personal health information. The patient and/or the patient's legally authorized guardian must acknowledge in writing that consent for specimen collection has been obtained, in accordance with institutional policies approved by the U.S. Department of Health and Human Services.

Exclusion Criteria:

* Women with psychological, psychiatric, or other conditions which prevent giving fully informed consent.
* Women whose underlying medical condition significantly increases their risk of complications from anesthesia and surgery.

• BACKGROUNDBlatt J. Pregnancy outcome in long-term survivors of childhood cancer. Med Pediatr Oncol. 1999 Jul;33(1):29-33. doi: 10.1002/(sici)1096-911x(199907)33:13.0.co;2-2. PMID 10401494
• BACKGROUNDMeirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001 Nov-Dec;7(6):535-43. doi: 10.1093/humupd/7.6.535. PMID 11727861
• BACKGROUNDGreenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33. doi: 10.3322/canjclin.50.1.7. PMID 10735013
• BACKGROUNDMeirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma. 1999 Mar;33(1-2):65-76. doi: 10.3109/10428199909093726. PMID 10194122
• BACKGROUNDMeirow D. Epidemiology and infertility in cancer patients. In: Gosden R, Tulandi T, editors. Preservation of fertility. London: Taylor and Francis, 2004:21-38.
• BACKGROUNDKoyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977 Apr;39(4):1403-9. doi: 10.1002/1097-0142(197704)39:43.0.co;2-8. PMID 851940
• BACKGROUNDGoldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990;1(3):183-8. doi: 10.1093/oxfordjournals.annonc.a057718. PMID 2261364
• BACKGROUNDChiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. Am J Epidemiol. 1999 Aug 1;150(3):245-54. doi: 10.1093/oxfordjournals.aje.a009995.